Comprehensive patent-claim and landscape analysis for US Patent 6,663,870 (United States)
What does US 6,663,870 claim, and what is the claim scope?
US 6,663,870 is a US utility patent with a claim set that defines a specific invention in a defined technical field, but the exact independent claim text and dependent-claim matrix are not provided here. Without the actual claim wording (or a full claim list), no complete, accurate claim-by-claim scope analysis can be produced.
What should be extracted to map claim scope to freedom-to-operate?
A complete scope analysis requires, at minimum, the patent’s:
- Independent claims (claim 1 and any other independent claims)
- Dependent claim dependencies
- Key limitations (structural, compositional, functional, process steps, parameter ranges)
- Defined terms used in the specification and incorporated into claims
- Claim construction-critical phrases (e.g., “comprising,” “consisting of,” “effective amount,” “substantially,” product-by-process boundaries)
What claim elements drive infringement risk?
Infringement and validity arguments usually hinge on:
- Whether the accused product/process meets every claimed limitation
- Whether functional limitations are supported by sufficiently specific structure or steps
- Whether parameter ranges are strict or “about” ranges
- Whether preamble language limits scope (often heavily litigated)
- Whether “comprising” open transitions invite non-exact replication
How strong is the patent estate for US 6,663,870 in the US?
A critical strength assessment requires the full patent family data, all related continuation/divisional filings, and later-cited patents, none of which are provided here. Without:
- The application number and filing/priority chain
- The full US publication/grant history
- Prosecution events and office actions
- Cited references and citing/cited relationships over time
- Any reexamination/inter partes review history
…the strength profile cannot be completed to a defensible, litigation-grade standard.
Patent landscape inputs that determine strength
A robust “strength” score in practice is driven by:
- Claim breadth vs. prior art coverage
- Whether independent claims were narrowed during prosecution
- How the specification supports each limitation
- Whether key limitations are novel vs. obvious combinations
- Litigation signals (assertion history, settlements, adverse rulings)
When does US 6,663,870 expire in the US, and what exclusivity windows apply?
Expiration timing requires the patent’s issue date, earliest effective filing date, and any term adjustments (including PTA and any terminal disclaimers). Those data are not supplied here.
What to compute for a defensible exclusivity timeline
To calculate a US expiration correctly, the workflow is:
- Determine earliest effective filing date (priority + non-provisional chain)
- Add 20 years from the earliest effective filing date (utility term)
- Add any granted Patent Term Adjustment (PTA) and subtract any terminal disclaimer effects
- Identify any patent term extension (PTE) if applicable (rare for many technology areas and only for specific drug/device contexts)
What prior art most likely anticipates or renders US 6,663,870 obvious?
Prior-art analysis cannot be completed without the patent’s claim text and the patent’s cited references (and ideally the prosecution history). Anticipation/obviousness mapping requires:
- A limitation-by-limitation comparison to the closest prior art
- Identification of the “teaching” features in non-patent literature and patents cited by the examiner
- Checking whether the cited art already discloses the combination of limitations across independent claims
How many later patents cite US 6,663,870, and what does that imply for validity and technological influence?
Citation mining requires access to the complete citing corpus and dates. Without that dataset:
- You cannot quantify how many patents cite the grant
- You cannot identify citation clusters (same assignee, same technology lane, same claim relevance)
- You cannot infer whether citations are generally affirming (building on the invention) or hostile (distinguishing over it)
Which companies are likely practicing around US 6,663,870, and which are potential challengers?
Identifying likely practicing companies and challengers requires either (a) inventor/assignee mapping plus continuation activity or (b) a litigation and patent assignment record. None is provided here.
What “challenger” signals should be checked
In a litigation-grade landscape, the list is typically built from:
- Paragraph IV filings (for drug patents) and related FDA submissions
- IPR filings naming the patent
- Declaratory judgment suits against users
- Assignment changes to investment entities
- Continuation filings by competitors trying to block design-arounds
What formulation, method-of-use, or delivery-system patents overlap with US 6,663,870?
Overlapping drug/formulation/delivery-system patents cannot be identified without knowing the technology category of US 6,663,870 and its claim subject matter. A correct overlap analysis depends on:
- Whether the patent is composition/product, method-of-use, device, or process
- Whether claims include formulation ranges, excipients, delivery systems, or dosing regimens
- Whether related US family members include complementary claims
How does US 6,663,870 compare with nearby patents in the same family or technology field?
Comparison requires a family tree and claim sets for neighboring members. Without the continuation/divisional list and the priority chain:
- You cannot establish claim evolution
- You cannot quantify incremental coverage
- You cannot map design-around risks across variants
What is the Orange Book status of US 6,663,870, and are there FDA pathway implications?
Orange Book status applies only to approved drug products with FDA-listed patents. Whether US 6,663,870 is listed cannot be determined here because drug/NDA/BLA identifiers are not provided.
What you would check for Orange Book linkage
- Whether the patent is listed in the Orange Book
- Which NDA/BLA it is tied to
- Patent type codes (composition, method-of-use, formulation)
- Listing expiration and any regulatory exclusivity that affects entry
What patent litigation affects US 6,663,870, including claim construction and settlements?
Litigation analysis needs docket-level data and rulings. Without:
- Parties and case numbers
- Court and venue
- Markman/claim construction outcomes
- Final invalidity or non-infringement judgments
- Settlement terms (if any) and stipulations
…the litigation impact cannot be produced.
What generic entry risks exist for products that might implicate US 6,663,870?
Generic-entry risk is product-specific and requires FDA labeling linkage (Orange Book, patents listed per NDA/BLA), plus Paragraph IV/notice data. Those are not available in the prompt.
Key Takeaways
No complete, accurate, or litigation-grade analysis of US Patent 6,663,870 can be produced from the provided input because the core inputs required for claim-scope, validity, citation, expiration, FDA linkage, and enforcement landscape are not included.
FAQs
1) What are the independent claims of US 6,663,870?
Cannot be answered accurately without the claim text.
2) What is the priority date and earliest effective filing date for US 6,663,870?
Cannot be answered from the provided input.
3) What is the expected US expiration date for US 6,663,870?
Cannot be computed without issue date, earliest effective filing date, and term adjustments.
4) Is US 6,663,870 listed in the Orange Book?
Cannot be determined from the provided input.
5) Has US 6,663,870 been challenged via inter partes review or litigation?
Cannot be determined from the provided input.
References
No sources were provided or cited in this response.
